孟鲁司特对镉毒性肾损害的保护作用:体内和体外实验

Q4 Pharmacology, Toxicology and Pharmaceutics
F. Kaviani, Missagh Jalali, E. Hoveizi, J. Jamshidian, Masumeh Ahmadizadeh
{"title":"孟鲁司特对镉毒性肾损害的保护作用:体内和体外实验","authors":"F. Kaviani, Missagh Jalali, E. Hoveizi, J. Jamshidian, Masumeh Ahmadizadeh","doi":"10.32598/ijt.15.4.422.2","DOIUrl":null,"url":null,"abstract":"Background: The protective effects of Montelukast (Mont), as an anti-inflammatory drug, against cadmium-induced kidney cell damage have already been studied and identified. Since the significant part of cadmium nephrotoxicity is caused by oxidative stress, this in vivo and in vitro study was conducted to investigate the possible role of Montelukast antioxidant properties in the protection. Methods: In the in vivo section, 42 rats were treated in seven groups of six rats as follows: Control; Cadmium Chloride (CdCl2) control; Montelukast control; CdCl2 plus Montelukast treatment; CdCl2 with Montelukast pre-treatment; Vitamin E control; CdCl2 plus Vitamin E treatment. In the in vitro section, human embryonic kidney cells (HEK293) were treated with CdCl2; Montelukast; Combined CdCl2 and Montelukast; Vitamin E; Combined CdCl2 and Vitamin E. Results: Montelukast, in both treatment and pretreatment forms, reduced serum urea, creatinine, and potassium levels compared to CdCl2 group, in vivo. Similar to vitamin E, the pre-treatment with Montelukast was associated with a significant decrease in Nitric Oxide (NO) and Total Antioxidant Capacity (TAC) in serum and renal tissue, and a significant increase in Glutathione Peroxidase (GPX) activity in serum compared those in the CdCl2 group. In the in vitro section of the study, Montelukast significantly reduced Malondialdehyde (MDA) and NO while the TAC level, Superoxide Dismutase (SOD), and the GPX activity increased significantly. Conclusion: Overall, the antioxidant effects of Montelukast appear to play a prominent role in preventing the renal toxicity due to cadmium exposure.","PeriodicalId":14637,"journal":{"name":"Iranian Journal of Toxicology","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Montelukast Protects Against Renal Damage Due to Cadmium Toxicity: In vivo and In vitro Experiments\",\"authors\":\"F. Kaviani, Missagh Jalali, E. Hoveizi, J. Jamshidian, Masumeh Ahmadizadeh\",\"doi\":\"10.32598/ijt.15.4.422.2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: The protective effects of Montelukast (Mont), as an anti-inflammatory drug, against cadmium-induced kidney cell damage have already been studied and identified. Since the significant part of cadmium nephrotoxicity is caused by oxidative stress, this in vivo and in vitro study was conducted to investigate the possible role of Montelukast antioxidant properties in the protection. Methods: In the in vivo section, 42 rats were treated in seven groups of six rats as follows: Control; Cadmium Chloride (CdCl2) control; Montelukast control; CdCl2 plus Montelukast treatment; CdCl2 with Montelukast pre-treatment; Vitamin E control; CdCl2 plus Vitamin E treatment. In the in vitro section, human embryonic kidney cells (HEK293) were treated with CdCl2; Montelukast; Combined CdCl2 and Montelukast; Vitamin E; Combined CdCl2 and Vitamin E. Results: Montelukast, in both treatment and pretreatment forms, reduced serum urea, creatinine, and potassium levels compared to CdCl2 group, in vivo. Similar to vitamin E, the pre-treatment with Montelukast was associated with a significant decrease in Nitric Oxide (NO) and Total Antioxidant Capacity (TAC) in serum and renal tissue, and a significant increase in Glutathione Peroxidase (GPX) activity in serum compared those in the CdCl2 group. In the in vitro section of the study, Montelukast significantly reduced Malondialdehyde (MDA) and NO while the TAC level, Superoxide Dismutase (SOD), and the GPX activity increased significantly. Conclusion: Overall, the antioxidant effects of Montelukast appear to play a prominent role in preventing the renal toxicity due to cadmium exposure.\",\"PeriodicalId\":14637,\"journal\":{\"name\":\"Iranian Journal of Toxicology\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian Journal of Toxicology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32598/ijt.15.4.422.2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32598/ijt.15.4.422.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

背景:孟鲁司特(Mont)作为一种抗炎药,对镉诱导的肾细胞损伤的保护作用已经被研究和确定。由于镉肾毒性的很大一部分是由氧化应激引起的,因此本研究通过体内和体外研究,探讨孟鲁司特抗氧化特性在保护镉肾毒性中的可能作用。方法:将42只大鼠分为7组,每组6只,分别为:对照组;氯化镉(CdCl2)控制;Montelukast控制;CdCl2 +孟鲁司特治疗;CdCl2与孟鲁司特预处理;维生素E控制;CdCl2加维生素E治疗。在体外切片中,用CdCl2处理人胚胎肾细胞(HEK293);Montelukast;CdCl2联合孟鲁司特;维生素E;结果:与CdCl2组相比,孟鲁司特治疗组和预处理组均降低了体内血清尿素、肌酐和钾水平。与维生素E类似,与CdCl2组相比,孟鲁司特预处理与血清和肾组织中一氧化氮(NO)和总抗氧化能力(TAC)显著降低相关,血清中谷胱甘肽过氧化物酶(GPX)活性显著升高相关。在体外切片研究中,孟鲁司特显著降低丙二醛(MDA)和NO, TAC水平、超氧化物歧化酶(SOD)和GPX活性显著升高。结论:综上所述,孟鲁司特的抗氧化作用在预防镉暴露肾毒性中发挥了重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Montelukast Protects Against Renal Damage Due to Cadmium Toxicity: In vivo and In vitro Experiments
Background: The protective effects of Montelukast (Mont), as an anti-inflammatory drug, against cadmium-induced kidney cell damage have already been studied and identified. Since the significant part of cadmium nephrotoxicity is caused by oxidative stress, this in vivo and in vitro study was conducted to investigate the possible role of Montelukast antioxidant properties in the protection. Methods: In the in vivo section, 42 rats were treated in seven groups of six rats as follows: Control; Cadmium Chloride (CdCl2) control; Montelukast control; CdCl2 plus Montelukast treatment; CdCl2 with Montelukast pre-treatment; Vitamin E control; CdCl2 plus Vitamin E treatment. In the in vitro section, human embryonic kidney cells (HEK293) were treated with CdCl2; Montelukast; Combined CdCl2 and Montelukast; Vitamin E; Combined CdCl2 and Vitamin E. Results: Montelukast, in both treatment and pretreatment forms, reduced serum urea, creatinine, and potassium levels compared to CdCl2 group, in vivo. Similar to vitamin E, the pre-treatment with Montelukast was associated with a significant decrease in Nitric Oxide (NO) and Total Antioxidant Capacity (TAC) in serum and renal tissue, and a significant increase in Glutathione Peroxidase (GPX) activity in serum compared those in the CdCl2 group. In the in vitro section of the study, Montelukast significantly reduced Malondialdehyde (MDA) and NO while the TAC level, Superoxide Dismutase (SOD), and the GPX activity increased significantly. Conclusion: Overall, the antioxidant effects of Montelukast appear to play a prominent role in preventing the renal toxicity due to cadmium exposure.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Iranian Journal of Toxicology
Iranian Journal of Toxicology Environmental Science-Health, Toxicology and Mutagenesis
CiteScore
1.60
自引率
0.00%
发文量
24
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信